Prospective Grant of Exclusive License: Treatment of Proliferative Disorders Using an Unexpected mTOR Kinase Inhibitor, 58864 [E7-20516]
Download as PDF
<![CDATA[
58864
Federal Register / Vol. 72, No. 200 / Wednesday, October 17, 2007 / Notices
Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
December 17, 2007 will be considered.
ADDRESSES: Requests for a copy of the
patent applications, inquiries,
comments and other materials relating
to the contemplated license should be
directed to: Fatima Sayyid, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4521; Facsimile:
(301) 402–0220; e-mail:
Fatima.Sayyid@nih.hhs.gov.
SUPPLEMENTARY INFORMATION: The
prospective exclusive license will be
royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
DATES:
Dated: October 11, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–20520 Filed 10–16–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Treatment of Proliferative
Disorders Using an Unexpected mTOR
Kinase Inhibitor
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
sroberts on PROD1PC70 with NOTICES
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the invention
embodied in PCT patent application
VerDate Aug<31>2005
19:05 Oct 16, 2007
Jkt 214001
PCT/US2004/041265 filed December 9,
2004, entitled: ‘‘Methods for
Suppressing an Immune Response or
Treating a Proliferative Disorder’’ [HHS
Reference Number: E–259–2003/0–PCT–
02], to Emiliem, Inc., a Delaware
Corporation, having a place of business
in Emeryville, California. The field of
use may be limited to the use of 2-(4piperazinyl) substituted 4H-1benzopyran-4-one compounds,
including 2-(4-piperazinyl)-8-phenyl4H-1-benzopyran-4-one (LY303511), for
the treatment of cancer and/or other
proliferative disorders not currently
licensed, excluding the treatment and
prevention of stenosis and restenosis.
The United States of America is an
assignee of the patent rights in these
inventions.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
December 17, 2007 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Susan Carson, D. Phil., Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Email: carsonsu@od.nih.gov; Telephone:
(301) 435–5020; Facsimile: (301) 402–
0220.
SUPPLEMENTARY INFORMATION: The
search for specific kinase inhibitors is
an active area of drug development as
there is a continued need for effective
anti-proliferative therapeutics with
acceptable toxicities. The core invention
is a novel method of use of one of the
4H-1-benzopyran-4-one derivatives
(LY303511) which has been shown to
target mTOR and casein kinase 2 (CK2)
without affecting PI3K activity (JPET,
May 26, 2005, doi: 10.1124/
jpet.105.083550). Proof of concept data
is available in an in vivo human
zenograft PC–3 prostate tumor model,
without observed toxicity. In vitro data
suggest that (2-(4-piperazinyl)-8-phenyl4H-1-benzopyran-4-one and derivatives
may be effective in treating
inflammatory, autoimmune and other
proliferative disorders including
restenosis, inflammatory bowel disease
and a variety of cancers. Method of use
claims are directed to derivatives of 2(4-piperazinyl)-substituted 4H-1benzopyran-4-one compounds as antiproliferative, immunosuppressive, antiinflammatory, anti-restenosis and antineoplastic agents.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: October 10, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–20516 Filed 10–16–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. COTP Corpus Christi 07–085]
South Texas Area Maritime Security
(STAMS) Committee; Vacancy
Coast Guard, DHS.
Solicitation for membership.
AGENCY:
ACTION:
SUMMARY: This notice requests
individuals interested in serving on the
South Texas Area Maritime Security
(STAMS) Committee to submit their
application for a potential opening on
the committee to the Corpus Christi
Captain of the Port/Federal Maritime
Security Coordinator.
DATES: Applications should reach the
Corpus Christi Captain of the Port/
Federal Maritime Security Coordinator
on or before October 30, 2007.
ADDRESSES: Requests for membership
should be submitted to the Captain of
the Port/Federal Maritime Security
Coordinator at the following address:
Commander, USCG Sector Corpus
Christi, 8930 Ocean Drive, Hangar 41,
Corpus Christi, Texas 78419.
FOR FURTHER INFORMATION CONTACT: Mr.
John Zarbock at 361–888–3162 (X501).
SUPPLEMENTARY INFORMATION:
Authority
Section 102 of the Maritime
Transportation Security Act (MTSA) of
2002 (Pub. L. 107–295) added section
70112 to Title 46 of the U.S. Code, and
authorized the Secretary of the
E:\FR\FM\17OCN1.SGM
17OCN1
]]>Agencies
[Federal Register Volume 72, Number 200 (Wednesday, October 17, 2007)]
[Notices]
[Page 58864]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-20516]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Treatment of
Proliferative Disorders Using an Unexpected mTOR Kinase Inhibitor
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is contemplating the
grant of an exclusive license to practice the invention embodied in PCT
patent application PCT/US2004/041265 filed December 9, 2004, entitled:
``Methods for Suppressing an Immune Response or Treating a
Proliferative Disorder'' [HHS Reference Number: E-259-2003/0-PCT-02],
to Emiliem, Inc., a Delaware Corporation, having a place of business in
Emeryville, California. The field of use may be limited to the use of
2-(4-piperazinyl) substituted 4H-1-benzopyran-4-one compounds,
including 2-(4-piperazinyl)-8-phenyl-4H-1-benzopyran-4-one (LY303511),
for the treatment of cancer and/or other proliferative disorders not
currently licensed, excluding the treatment and prevention of stenosis
and restenosis. The United States of America is an assignee of the
patent rights in these inventions.
DATES: Only written comments and/or application for a license, which
are received by the NIH Office of Technology Transfer on or before
December 17, 2007 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Susan Carson, D. Phil., Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; Email: carsonsu@od.nih.gov;
Telephone: (301) 435-5020; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: The search for specific kinase inhibitors is
an active area of drug development as there is a continued need for
effective anti-proliferative therapeutics with acceptable toxicities.
The core invention is a novel method of use of one of the 4H-1-
benzopyran-4-one derivatives (LY303511) which has been shown to target
mTOR and casein kinase 2 (CK2) without affecting PI3K activity (JPET,
May 26, 2005, doi: 10.1124/jpet.105.083550). Proof of concept data is
available in an in vivo human zenograft PC-3 prostate tumor model,
without observed toxicity. In vitro data suggest that (2-(4-
piperazinyl)-8-phenyl-4H-1-benzopyran-4-one and derivatives may be
effective in treating inflammatory, autoimmune and other proliferative
disorders including restenosis, inflammatory bowel disease and a
variety of cancers. Method of use claims are directed to derivatives of
2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compounds as anti-
proliferative, immunosuppressive, anti-inflammatory, anti-restenosis
and anti-neoplastic agents.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 10, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-20516 Filed 10-16-07; 8:45 am]
BILLING CODE 4140-01-P
